PulteGroup, Inc. vs Sana Biotechnology Inc — how do they compare? PulteGroup, Inc. trades at $126.7 (market cap $23.67B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: PulteGroup, Inc. is far larger — about 26.9× Sana Biotechnology Inc's market cap, and PulteGroup, Inc. pays a 0.84% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| PHM | SANA | |
|---|---|---|
Market Cap | $23.67B | $879.40M |
Sector | Consumer Cyclical | Health |
52-Week High | $142.56 | $5.92 |
52-Week Low | $110.11 | $2.68 |
Enterprise Value | $23.63B | $853.59M |
Dividend Yield | 0.84% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Trailing returns across standard periods
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →